Vaxart Inc VXRT

Healthcare Biotechnology

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccine candidates designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine candidate for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine candidate that protect against norovirus GI and norovirus GII, by targeting the norovirus GI.1 Norwalk strain and the norovirus GII.4 Sydney strain; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer.

NDAQ:VXRT - Post by User

Vaxart Inc

<< Previous

Bullboard Posts

Next >>

(8)
•••

Post by Dalahlamaon Feb 08, 2021 11:10pm

116 Views

Post# 32509333

Up 23% in one day

And it's just a start. This next wave will continue to rise at least the next week and looks like a promising long term medical investment to add to your portfolio.

<< Previous

Bullboard Posts

Next >>

This stock is ready to capture the lead in the diabetes market